Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 10/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19656711 | 0.89 | CFTR (0.54) | CFTRHTR2APDE4DSCN5AMAPK14 | |
| SCHEMBL19656761 | 0.89 | CFTR (0.54) | CFTRHTR2APDE4DSCN5AMAPK14 | |
| SCHEMBL17793903 | 0.86 | CFTR (0.48) | CFTRHTR2APDE4DSCN5A | |
| SCHEMBL19656691 | 0.84 | CFTR (0.47) | CFTRHTR2APDE4DSCN5AACSS2 | |
| SCHEMBL19651548 | 0.82 | CFTR (0.47) | CFTRHTR2APDE4DSCN5A | |
| SCHEMBL19651573 | 0.82 | CFTR (0.62) | CFTRHTR2APDE4DSCN5AMAPK14 | |
| SCHEMBL17793953 | 0.79 | CFTR (0.41) | CFTRHTR2APDE4DSCN5A | |
| SCHEMBL29592296 | 0.78 | CFTR (0.59) | CFTRHTR2APDE4DSCN5AMAPK14 | |
| SCHEMBL19412365 | 0.78 | CFTR (0.59) | CFTRHTR2APDE4DSCN5AMAPK14 | |
| SCHEMBL19027867 | 0.76 | CFTR (0.55) | CFTRHTR2APDE4DSCN5AMAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CATABASIS PHARMACEUTICALS, INC. | 2017-11-30 | — | — | US | disclosed |
| WO-2016086136-A1 | FATTY ACID CYSTEAMINE CONJUGATES OF CFTR MODULATORS AND THEIR USE IN TREATING MEDICAL DISORDERS | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CPT2, FABP1, ACAA2 | CFTR 182/4885HTR2A 2500/4885PDE4D 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.